摘要
目的:观察通宣理肺颗粒联合布地奈德福莫特罗吸入剂治疗慢性阻塞性肺疾病(COPD)急性发作期的临床疗效。方法:选取84例COPD急性发作期患者,依据随机数字表法分成对照组和观察组各42例。对照组给予布地奈德福莫特罗吸入剂治疗,观察组在对照组基础上给予通宣理肺颗粒治疗,2组均治疗7 d。比较2组临床疗效、不良反应发生率;比较2组治疗前后用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))、FEV_(1)/FVC、圣乔治呼吸问卷(SGQR)评分、6 min步行试验距离(6MWD)及症状积分。结果:观察组总有效率95.24%,高于对照组78.57%(P<0.05)。治疗后,2组FVC、FEV_(1)及FEV_(1)/FVC均较治疗前升高(P<0.05),观察组FVC、FEV_(1)及FEV_(1)/FVC均高于对照组(P<0.05)。治疗后,2组SGQR评分均较治疗前降低(P<0.05),6MWD均较治疗前增大(P<0.05);观察组SGQR评分低于对照组(P<0.05),6MWD大于对照组(P<0.05)。治疗后,2组咳嗽、咳痰、喘憋积分均较治疗前降低(P<0.05),观察组咳嗽、咳痰、喘憋积分均低于对照组(P<0.05)。观察组不良反应发生率11.90%,对照组不良反应发生率9.52%,2组比较,差异无统计学意义(P>0.05)。结论:通宣理肺颗粒联合布地奈德福莫特罗吸入剂治疗COPD急性发作期疗效较好,能改善患者的临床症状、肺功能、运动耐力及生活质量,安全性高。
Objective: To observe the clinical effect of Tongxuan Lifei granules combined with budesonide formoterol inhalation on chronic obstructive pulmonary disease(COPD) in acute attack stage. Methods:A total of 84 patients with COPD in acute attack stage were selected and divided into the control group and the observation group according to the random number table method,with 42 cases in each group. The control group was treated with budesonide formoterol inhalation,and the observation group was additionally treated with Tongxuan Lifei granules based on the treatment of the control group.Both groups were treated for seven days. The clinical effects and incidence of adverse reactions were compared between the two groups;before and after treatment,the forced vital capacity(FVC),forced expiratory volume in one second(FEV_(1)),FEV_(1)/FVC,numbers of acute attacks,scores of Saint George Respiratory questionnaire(SGQR),Six-Minute Walk Distance(6MWD) and syndrome scores were compared between the two groups. Results:The total effective rate was 95.24% in the observation group,higher than that of 78.57% in the control group(P<0.05). After treatment,the FVC,FEV_(1)and FEV_(1)/FVC in the two groups were increased when compared with those before treatment(P<0.05), and the above indexes in the observation group were higher than those in the control group(P<0.05). After treatment, the SGQR scores in both groups were decreased when compared with those before treatment(P<0.05),and the 6MWD was increased(P<0.05);the SGQR score in the observation group was lower than that in the control group(P<0.05), and the 6MWD was longer(P<0.05). After treatment,the scores of cough,expectoration and heavy breath in the two groups were decreased when compared with those before treatment(P<0.05),and the above scores in the observation group were lower than those in the control group(P<0.05). The incidence of adverse reactions was 11.90% in the observation group,and 9.52% in the control group,there being no significance in the difference(P>0.05). Conclusion: The therapy of Tongxuan Lifei granules combined with budesonide formoterol inhalation has a good curative effect on COPD in acute attack stage,which can improve the clinical symptoms,lung function,exercise endurance and quality of life of patients,with high safety.
出处
《新中医》
CAS
2022年第8期85-88,共4页
New Chinese Medicine
关键词
慢性阻塞性肺疾病
急性发作期
通宣理肺颗粒
布地奈德福莫特罗吸入剂
肺功能
圣乔治呼吸问卷
6
min步行试验距离
症状积分
Chronic obstructive pulmonary disease
Acute attack stage
Tongxuan Lifei granules
Budesonide formoterol inhalation
Lung function
Saint George Respiratory Questionnaire
Six-minute walk distance
Syndrome scores
